Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Equity Income: 2018-2024

Historic Equity Income for Ascendis Pharma A (ASND) over the last 7 years, with Dec 2024 value amounting to -$21.7 million.

  • Ascendis Pharma A's Equity Income fell 82.84% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 148.39%. This contributed to the annual value of -$21.7 million for FY2024, which is 9.70% down from last year.
  • Per Ascendis Pharma A's latest filing, its Equity Income stood at -$21.7 million for FY2024, which was down 9.70% from -$19.8 million recorded in FY2023.
  • Ascendis Pharma A's 5-year Equity Income high stood at $13.8 million for FY2021, and its period low was -$21.7 million during FY2024.
  • Over the past 3 years, Ascendis Pharma A's median Equity Income value was -$19.8 million (recorded in 2023), while the average stood at -$19.9 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Equity Income tumbled by 133,934.94% in 2020, and later spiked by 226.67% in 2021.
  • Ascendis Pharma A's Equity Income (Yearly) stood at -$10.9 million in 2020, then skyrocketed by 226.67% to $13.8 million in 2021, then crashed by 231.08% to -$18.1 million in 2022, then declined by 9.62% to -$19.8 million in 2023, then dropped by 9.70% to -$21.7 million in 2024.